Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has received an average rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $32.90.
Several analysts recently issued reports on NRIX shares. Morgan Stanley started coverage on Nurix Therapeutics in a research note on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target for the company. SVB Leerink reduced their price target on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating for the company in a research note on Tuesday, December 13th. Finally, HC Wainwright reduced their price target on Nurix Therapeutics to $53.00 in a research note on Thursday, October 13th.
Get
Nurix Therapeutics alerts:
Institutional Trading of Nurix Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Swiss National Bank raised its holdings in shares of Nurix Therapeutics by 8.0% during the 1st quarter. Swiss National Bank now owns 47,500 shares of the company's stock worth $665,000 after buying an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Nurix Therapeutics by 34.1% during the 1st quarter. JPMorgan Chase & Co. now owns 120,516 shares of the company's stock worth $1,688,000 after buying an additional 30,664 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Nurix Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 18,670 shares of the company's stock worth $262,000 after buying an additional 6,891 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Nurix Therapeutics by 4.9% during the 1st quarter. Rhumbline Advisers now owns 33,511 shares of the company's stock worth $469,000 after buying an additional 1,573 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Nurix Therapeutics by 104.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,525 shares of the company's stock worth $3,328,000 after buying an additional 121,167 shares in the last quarter. 91.33% of the stock is currently owned by institutional investors.
Nurix Therapeutics Trading Down 2.9 %
NRIX stock opened at $12.10 on Friday. The firm has a market capitalization of $570.49 million, a PE ratio of -3.26 and a beta of 1.63. Nurix Therapeutics has a 1-year low of $7.52 and a 1-year high of $20.20. The business's 50 day simple moving average is $11.70 and its 200 day simple moving average is $13.60.
Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
